Cramer's Lightning Round - Don't Sell Celldex (9/19/13)

|
 |  Includes: CLDX, KEY, RCL, SSYS, TTWO, XONE
by: Miriam Metzinger

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday September 19.

Bullish Calls:

Celldex Therapeutics (NASDAQ:CLDX): "We discussed selling it because it has doubled. We did recommend it dramatically lower, but the actual stuff in the pipeline is so good, we will not sell."

Royal Caribbean (NYSE:RCL): "They took a lot of share ... This is a perfect situation. It is excellent."

Take-Two Interactive (NASDAQ:TTWO): "Management has pulled it off. TTWO has done a great job. It can go much higher."

Stratasys (NASDAQ:SSYS): "It did a secondary and is ramping (SSYS is Cramer's favorite stock in the 3-D printing space), but on speculation only."

Bearish Calls:

KeyCorp (NYSE:KEY): "I had to ring the register (KEY is a holding in Cramer's charitable trust). It is up really big, and this company does not do well with this yield curve, even though it has great management."

ExOne (NASDAQ:XONE): Cramer prefers Stratasys for 3-D printing.

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Jim Cramer's Action Alerts PLUS: Trade right alongside a Wall Street pro! Start your 14-day FREE trial today.

Get Cramer's Picks by email - it's free and takes only a few seconds to sign up.